Latest Content

For patients navigating a cancer diagnosis, there is a hidden complication that requires vigilance: the risk of a pulmonary embolism.

For me, Colorectal Cancer Awareness Month is about my brother, Jimmy, who died from colorectal cancer at the age of 36.

New findings from the phase 3 SENTRY trial offer encouraging news for patients with myelofibrosis.

Topical HT-001 reduced rash and irritation from EGFR therapies with low levels in the bloodstream and no serious side effects in patients with cancer.

A son shares his decision to become a living liver donor, offering his father a second chance after a cancer diagnosis.

Dr. Amengual outlines how patients with relapsed lymphoma can approach clinical trials, including phases, eligibility and key questions to ask providers.

A couple shares how self advocacy, preparation and caregiver support shaped their experience navigating liver cancer care.

Dr. Wendy Woodward discussed the transformative rise of hypofractionated radiation.

The FDA approved a steroid-sparing Tecvayli and Darzalex Faspro combo for relapsed myeloma, offering an 83% reduction in disease progression risk.

Zegfrovy helped patients live longer without cancer growth and improved tumor response compared with chemotherapy in first-line lung cancer treatment.

A living liver donor shares recovery, fatigue and the lasting reward of helping his father heal after transplant surgery.

An overview of stage 1 lymphocyte-rich Hodgkin lymphoma covers diagnosis, treatment options and side effects to help guide patient care decisions.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer.